Years ago I had a friend, who worked for Burroughs and after the merger with Sperry, another great company and the subsequent name change and downfall to unisys, was so frustrated that he used to call any company that ended with sys substitute with sheet, i.e unisheet, infosheet, linksheet etc and he was never wrong, every company ending with sys has ended with a disaster and mosheet has been no exception.
Adam Feuerstein just posted a study on CBD, on his twitter, that shows it is pretty ineffective and the effect if any does not last. I recall 60 minutes made a similar sensational program on resveretrol that proved to be a complete and utter failure.
reverse split and more dilution is coming. lets face it minor movements on the scale is not going to impress anyone in an open label phase one study in which 20% of the subjects did not even feel the placebo effect.
Without the company announcing liquidation accumulation of shares at cheap would not have been possible. Were the management coerced in announcing liquidation so the accumulation for hostile take over could take place? Shareholders lost big time on this deal, because it is the end of the year tax loss season and a lot of share holders sold when they saw the liquidation announcement. The management could have negotiated a better deal for the share holder if they had not announced the last quidation.
It shows you something about the American Economy....
Thanks for the details. He still owns 1 million shares or possibly sold or put 800k shares in cold storage. I think the reasons the stock tanked is the FDA's insistence in designing a better trial. Once they agree to the stratification method for the ECG data the trial and s a go. Hopefully this quarter.
Oppenheimer analyst spoke to the company and the follow up CV test is only for the patients that discontinue the drug in the trial for any reason. They want to make sure to hat patients that go off the drug also monitored for heart valve performanc. This would validate the claim by the company that this should not add to the drug dev timeline.
It is going smoothly and CV is a concern with this drug and they just want a follow up. The question is will the parents who will have seen their kids seizure free while on the drug, will agree to go off the drug for 3 or 6 months just to get the followup CV test results. I guess for the sake of science they will have to. If FDA did not want this drug developed they wouldn't have given them Orphan designation.
ZX008 previously received ORPHAN DRUG DESIGNATION from the FDA, and is expected to enter Phase 3 clinical studies during the fourth quarter of 2015 for the treatment of Dravet syndrome, a rare and debilitating form of epilepsy that begins in infancy.
RBP-7000 and Relday appear to have a similar performance, but RBP-7000 requires reconstitution at the time of injection and therefore has to have needle injection. Relday does not require reconstitution and can use the needle-less injector that Zogenix offers. With needle-less injection you know for sure you are doing a subcutaneous injection--no potential lawsuits.
Everyone is speculating that Hillary is going to cause another nuclear winter like the first time she was in charge of the health care. This time she has to get elected first before she can do any damage. Her chance of election is slim and none. Besides we should have around 134million in the bank by the end of the year and 10 million more coming out of escrow early next year. Can't be in a better financial position than we are now. We have more than enough money to finish the two phase 3 trials and do some other proof of concept trials in other forms of epilepsy. There were those who were worried about IP they rolled that out in the latest Sept presentation and I did an application search and they are all there. The fact that they are not going to finance Relday on their own is a positive and should preserve significant amount of cash.
To be frank with you having the guy who has his skin in the game running the company is a plus.
time to buy